Pfizer-BioNTech’s COVID-19-and-flu combination drug meets 1 of 2 trial objectives
Pfizer and BioNTech said Friday that a Phase 3 trial of their COVID-19-and-influenza combination vaccine candidate met one of its two objectives.
Pfizer and BioNTech said Friday that a Phase 3 trial of their COVID-19-and-influenza combination vaccine candidate met one of its two objectives.
